All CIRM Grants

Institution Researcher name Grant Type Grant Title Award Value
Stanford University Alan Cheng New Faculty Physician Scientist Enhancing hair cell regeneration in mouse and human inner ear $3,091,595
Ludwig Institute for Cancer Research Webster Cavenee Disease Team Planning Stem Cell-Mediated Oncocidal Therapy of Primary & Metastatic Brain Tumors $3,867
Cellular Dynamics International Thomas Novak hiPSC Derivation Generation and characterization of high-quality, footprint-free human induced pluripotent stem cell lines from 3,000 donors to investigate multigenic diseases $16,000,000
Gladstone Institutes Steven Finkbeiner Early Translational IV Development of Novel Autophagy Inducers to Block the Progression of and Treat Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Diseases $2,278,080
Stanford University Michael Cleary Basic Biology IV Prostaglandin pathway regulation of self-renwal in hematopoietic and leukemia stem cells $1,244,455
University of California, Davis Laura Marcu Tools and Technologies III Multimodal platform combining optical and ultrasonic technologies for in vivo nondestructive evaluation of engineered vascular tissue constructs $1,834,474
University of California, Los Angeles Denis Evseenko Basic Biology V Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes $411,330
Scripps Research Institute James Williamson Creativity Awards Stem Cell Summer Academy: Creating the Next Generation of Scientists $205,122
University of California, Davis Roslyn Isseroff Preclinical Development Awards Scaffold for dermal regeneration containing pre-conditioned mesenchymal stem cells to heal chronic diabetic wounds $4,620,144
University of California, Irvine Lisa Flanagan Basic Biology V Molecular basis of plasma membrane characteristics reflecting stem cell fate potential $994,108
University of California, Santa Barbara Glenn Lucas Major Facilities UC Santa Barbara Bio Sciences II $3,205,800
University of California, San Diego Mana Parast New Faculty Physician Scientist Human pluripotent stem cell-based therapeutics for preeclampsia $2,974,750
Children's Hospital of Oakland Research Institute Mark Walters Disease Team Planning CIRM Disease Team Planning Award $16,939
Coriell Institute for Medical Research Cristian Perez hPSC Repository The CIRM Human Pluripotent Stem Cell Biorepository – A Resource for Safe Storage and Distribution of High Quality iPSCs $9,942,175
University of California, Los Angeles Stanley Nelson Early Translational from Disease Team Conversion Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy $1,823,545
University of California, Davis Deborah Lieu Basic Biology IV Induction of Pluripotent Stem Cell-Derived Pacemaking Cells $1,333,800
Stanford University Fan Yang Tools and Technologies III Injectable Macroporous Matrices to Enhance Stem Cell Engraftment and Survival $1,438,200
Cedars-Sinai Medical Center Paul Noble Basic Biology V Innate Immune Regulation of Lung Alveolar Stem Cell Renewal in Mouse and Man $624,816
University of California, San Francisco Katherine Nielsen Creativity Awards [REDACTED] SEP High School Intern Program $175,522
Scripps Health Darryl D'Lima Preclinical Development Awards Embryonic Stem Cell-Derived Chondroprogenitor Cells to Repair Osteochondral Defects $7,660,211
University of California, San Diego Christian Metallo Basic Biology V Metabolic regulation of cardiac differentiation and maturation $1,124,834
University of California, Santa Cruz Margaret Delaney Major Facilities UC Santa Cruz IBSC Facility $7,191,950
University of California, San Francisco Ophir Klein New Faculty Physician Scientist Stem cell therapy for inflammatory bowel disease $3,084,000
Cedars-Sinai Medical Center Eduardo Marbán Disease Team Planning {REDACTED} Heart Disease Regenerative Medicine Team Planning Award $38,980
ViaCyte, Inc. Howard Foyt Strategic Partnership I Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes $10,075,070
City of Hope Yanhong Shi Basic Biology IV Modeling Alexander disease using patient-specific induced pluripotent stem cells $1,367,172
University of California, Los Angeles Irvin Chen Early Translational from Disease Team Conversion HPSC based therapy for HIV disease using RNAi to CCR5. $1,505,000
University of California, San Francisco Miguel Ramalho-Santos Basic Biology IV Genetic dissection of human cellular reprogramming to pluripotency $1,184,883
Stanford University Sarah Heilshorn Tools and Technologies III Injectable Hydrogels for the Delivery, Maturation, and Engraftment of Clinically Relevant Numbers of Human Induced Pluripotent Stem Cell-Derived Neural Progenitors to the Central Nervous System $1,347,767
University of California, San Diego Cornelis Murre Basic Biology V Epigenetic mechanisms that enforce pluripotency in embryonic stem cells $1,161,000
University of California, Davis Gerhard Bauer Creativity Awards Internship at a Cutting Edge CIRM-funded Stem Cell Research Facility $250,064
Stanford University Matthew Porteus Preclinical Development Awards Pre-clinical development of gene correction therapy of hematopoietic stem cells for SCID-X1 $874,877
ViaCyte, Inc. Howard Foyt Accelerated Development Pathway I Clinical Development of a Cell Therapy for Diabetes $16,603,160
University of California, Los Angeles Samantha Butler Basic Biology V Assessing the mechanism by which the Bone Morphogenetic Proteins direct stem cell fate $545,962
University of California, San Francisco A. Washington Major Facilities UCSF CIRM Building $34,862,400
University of California, San Francisco Jason Pomerantz New Faculty Physician Scientist Characterization of Human Skeletal Muscle Stem Cells for Clinical Application $3,084,000
University of California, Irvine Leslie Thompson Disease Team Planning Huntington's Disease Team $41,953
University of California, San Diego Maike Sander Basic Biology IV Deciphering transcriptional control of pancreatic beta-cell maturation in vitro $1,258,560
University of California, San Diego Lawrence Goldstein Early Translational from Disease Team Conversion Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis $4,139,754
Buck Institute for Age Research Deepak Lamba Basic Biology IV 3D Modeling of Retina using Polymer Scaffolds for Understanding Disease Pathogenesis $1,212,553
University of California, Irvine Mathew Blurton-Jones Tools and Technologies III Optimizing the differentiation and expansion of microglial progenitors from human pluripotent stem cells for the study and treatment of neurological disease. $1,147,596
Asterias Biotherapeutics Jane Lebkowski Strategic Partnership III Track A A Phase I/IIa Dose Escalation Safety Study of [REDACTED] in Patients with Cervical Sensorimotor Complete Spinal Cord Injury $14,323,318
University of California, San Francisco Mark Anderson Basic Biology V Generation of a functional thymus to induce immune tolerance to stem cell derivatives $1,191,000
City of Hope Paul Salvaterra Creativity Awards Creativity Award Program in Stem Cell Biology for California High School Students $260,825
Cedars-Sinai Medical Center Shaomei Wang Late Stage Preclinical Projects IND-enabling study of subretinal delivery of human neural progenitor cells for the treatment of retinitis pigmentosa $4,954,514
University of California, San Diego Catriona Jamieson Alpha Stem Cell Clinics Alpha Stem Cell Clinic for the Development of Regenerative Therapies $7,999,137
University of California, San Diego Lawrence Goldstein Basic Biology V Elucidating pathways from hereditary Alzheimer mutations to pathological tau phenotypes $1,050,300
Palo Alto Institute for Research and Education Thomas Rando Basic Biology V Molecular regulation of stem cell potency $966,510
University of Southern California Chrysostomos Nikias Major Facilities Broad CIRM Facility at USC $26,972,500
University of California, San Francisco Ann Zovein New Faculty Physician Scientist Human endothelial reprogramming for hematopoietic stem cell therapy. $2,319,784
Children's Hospital of Los Angeles Donald Kohn Disease Team Planning STEM CELL GENE THERAPY FOR SICKLE CELL DISEASE $12,131
Numerate, Inc. John Griffin Early Translational IV Use of human iPSC-derived neurons from Huntington’s Disease patients to develop novel, disease-modifying small molecule structural corrector drug candidates targeting the unique, neurotoxic conformation of mutant huntingtin $520,015
Sanford-Burnham Medical Research Institute Huei-sheng Chen Basic Biology IV Studying Arrhythmogenic Right Ventricular Dysplasia with patient-specific iPS cells $1,582,606
Sangamo BioSciences, Inc. Fyodor Urnov Strategic Partnership II A Treatment For Beta-thalassemia via High-Efficiency Targeted Genome Editing of Hematopoietic Stem Cells $2,760,540
University of California, San Francisco Jeremy Reiter Basic Biology IV Modeling disease in human embryonic stem cells using new genetic tools $1,387,800
Stanford University Irving Weissman Tools and Technologies III Identification and isolation of transplantable human hematopoietic stem cells from pluripotent cell lines; two steps from primitive hematopoiesis to transplantable definitive cells, and non-toxic conditioning of hosts for hematopoeitic stem cell transplan $1,341,403
City of Hope John Zaia Strategic Partnership III Track A A Phase I, Open-Label Study to Assess the Safety, Feasibility and Engraftment of Zinc Finger Nucleases (ZFN) CCR5 Modified Autologous CD34+ Hematopoietic Stem/Progenitor Cells with Escalating Doses of Busulfan in HIV-1 (R5) Infected Subjects with Suboptim $5,583,438
Stanford University Helen Blau Basic Biology V Mass Cytometry to Delineate the Human Muscle Stem Cell Hierarchy and Dysfunction in Aging $1,175,357
Gladstone Institutes Shannon Noonan Creativity Awards [REDACTED] Summer Scholars internship program $35,044
Caladrius Biosciences, Inc. Robert Dillman Clinical Trial Stage Projects Tumor stem cell-targeted immunotherapy for metastatic melanoma –a randomized phase 3 clinical trial. $3,000,000
University of California, Los Angeles John Adams Alpha Stem Cell Clinics Alpha Stem Cell Clinic (ASCC) Consortium $8,000,000
University of California, Merced Kara McCloskey Basic Biology V Directed Differentiation of Specialized Endothelial Cells $476,052
University of California, San Francisco Jeffrey Bluestone Disease Team Planning A CIRM Disease Team for the Treatment and Cure of Diabetes $55,000
Stanford University Michelle Monje New Faculty Physician Scientist White matter neuroregeneration after chemotherapy: stem cell therapy for “chemobrain” $2,800,536
Sanford-Burnham Medical Research Institute Mark Mercola Disease Team Planning "Stem Cell Therapies for Heart Failure" $44,450
Sanford-Burnham Medical Research Institute Stuart Lipton Early Translational IV Programming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke $1,020,815
Stanford University Howard Chang Basic Biology IV Long noncoding RNAs for pluripotency and cell fate commitment $1,386,627
University of California, San Diego Thomas Kipps Disease Team Therapy Development III Therapeutic Eradication of Cancer Stem Cells $4,179,598
Stanford University Alexander Dunn Basic Biology IV Role of mechanical signaling in stem cell self-renewal and differentiation $1,064,224
University of Southern California Paula Cannon Tools and Technologies III Site-specific gene editing in hematopoietic stem cells as an anti-HIV therapy $1,499,400
Salk Institute for Biological Studies Ronald Evans Basic Biology V Metabolically-driven epigenetic changes in iPSC reprogramming $1,491,900
University of Southern California Roberta Brinton Creativity Awards CIRM STAR High School Summer Research and Creativity Program $271,160
The Scintillon Institute Stuart Lipton Early Translational IV Programming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke $1,103,185
City of Hope John Zaia Alpha Stem Cell Clinics The Innovation-Alpha Clinic for Cellular Therapies (I-ACT) – A Program for the Development and Delivery of Innovative Cell-based Treatments and Cures for Life-threatening Diseases. $8,000,000
Gladstone Institutes Sheng Ding Basic Biology V A novel druggable mechanism to safeguard stem cell genome $1,423,800
University of Southern California David Woodley Disease Team Planning Clinical Regenerative Wound Healing With Stem Cells $33,626
University of California, San Francisco Tippi MacKenzie New Faculty Physician Scientist In Utero Embryonic Stem Cell Transplantation to Treat Congenital Anomalies $2,661,742
City of Hope Michael Barish Disease Team Planning Genetically-modified neural stem cells for treatment of high-grade glioma $55,000
Stanford University Michele Calos Early Translational IV Engineered iPSC for therapy of limb girdle muscular dystrophy type 2B $1,876,253
Gladstone Institutes Steven Finkbeiner Basic Biology IV Common molecular mechanisms in neurodegenerative diseases using patient based iPSC neurons $1,482,025
Stanford University Irving Weissman Disease Team Therapy Development III Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors $6,505,568
University of California, San Diego George Sen Basic Biology IV Regulation of Epidermal Self-Renewal and Differentiation by Histone and DNA Demethylases. $1,080,000
University of Southern California Qilong Ying Tools and Technologies III Embryonic stem cell-based generation of small animal models for assessing human cellular therapies $1,334,160
University of California, Los Angeles Bennett Novitch Basic Biology V In vitro modeling of human motor neuron disease $1,148,758
University of California, Davis Emanual Maverakis New Faculty Physician Scientist Tunable hydrogels for therapeutic delivery of multipotent stem cells. $2,772,000
University of California, Davis Mehrdad Abedi Clinical Trial Stage Projects Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients $8,414,265
City of Hope Larry Couture Tools and Technologies III Development of a scalable, practical, and transferable GMP-compliant suspension culture-based differentiation process for cardiomyocyte production from human embryonic stem cells. $899,728
University of California, San Diego Dianne McKay Basic Biology V Role of intracytoplasmic pattern recognition receptors in HSC engraftment $615,639
University of California, San Francisco Jeffrey Lotz Disease Team Planning A CIRM Disease Team for the Repair of Traumatically Injured and Arthritic Cartilage $33,172
Cedars-Sinai Medical Center Robert Baloh New Faculty Physician Scientist Human iPSC modeling and therapeutics for degenerative peripheral nerve disease $3,031,737
University of California, San Diego Dennis Carson Disease Team Planning CIRM Planning Grant in Leukemia $52,174
University of California, Los Angeles Robert Reiter Early Translational IV Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells $4,075,668
Gladstone Institutes Benoit Bruneau Basic Biology IV Epigenetic regulation of human cardiac differentiation $1,708,560
University of California, Los Angeles Donald Kohn Disease Team Therapy Development III Clinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease $13,145,465
University of California, Los Angeles Kathrin Plath Basic Biology IV Understanding the status of the X chromosomes in human ESCs and preimplantation embryos $1,382,400
University of California, San Francisco Andrew Leavitt Tools and Technologies III Small molecule tools and scale-up technologies to expand human umbilical cord blood stem and progenitor cells for clinical and research use $1,416,600
Stanford University Michael Snyder Genomics Centers of Excellence Awards (R) Center of Excellence for Stem Cell Genomics $22,796,609
University of California, San Francisco Valerie Weaver Basic Biology V Biophysical Determinants of Early Embryonic Stem Cell Fate Specification $1,186,500
University of California, Los Angeles Ali Nsair New Faculty Physician Scientist Human Induced Pluripotent Stem Cell-Derived Cardiovascular Progenitor Cells for Cardiac Cell Therapy. $3,004,315
University of California, Los Angeles Donald Kohn Clinical Trial Stage Projects A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease $7,083,364

Pages